U Bacher

Summary

Affiliation: University Medical Center Hamburg-Eppendorf
Country: Germany

Publications

  1. pmc Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
    Ulrike Bacher
    Department for Stem Cell Transplantation, University of Hamburg, 20246 Hamburg, Germany
    Blood 120:4256-62. 2012
  2. ncbi request reprint Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
    Ulrike Bacher
    Department for Stem Cell Transplantation, University Cancer Centre Hamburg, Martinistrasse 52, Hamburg, Germany
    Br J Haematol 153:149-67. 2011
  3. doi request reprint Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia
    Ulrike Bacher
    Department for Stem Cell Transplantation, University of Hamburg Eppendorf, Germany
    ScientificWorldJournal 11:310-9. 2011
  4. doi request reprint Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Martinistr 52, 20246 Hamburg, Germany
    Cancer Genet Cytogenet 203:169-75. 2010
  5. doi request reprint Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1649-57. 2010
  6. doi request reprint Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1-11. 2010
  7. doi request reprint Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Germany
    Clin Exp Med 10:205-8. 2010
  8. doi request reprint Safety of conditioning agents for allogeneic haematopoietic transplantation
    Ulrike Bacher
    University Cancer Center Hamburg, Department of Stem Cell Transplantation, Martinistr 52, 20246 Hamburg, Germany
    Expert Opin Drug Saf 8:305-15. 2009
  9. doi request reprint Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University Medical Center Hamburg UCCH, Martinistr 52, Hamburg 20246, Germany
    Ann Hematol 88:1207-13. 2009
  10. doi request reprint Interactive diagnostics in the indication to allogeneic SCT in AML
    U Bacher
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Bone Marrow Transplant 43:745-56. 2009

Detail Information

Publications23

  1. pmc Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
    Ulrike Bacher
    Department for Stem Cell Transplantation, University of Hamburg, 20246 Hamburg, Germany
    Blood 120:4256-62. 2012
    ..In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse...
  2. ncbi request reprint Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
    Ulrike Bacher
    Department for Stem Cell Transplantation, University Cancer Centre Hamburg, Martinistrasse 52, Hamburg, Germany
    Br J Haematol 153:149-67. 2011
    ..This review summarizes the current status of pharmacotherapy and transplantation in CMML and outlines recent results of molecular research for diagnosis of this heterogeneous entity...
  3. doi request reprint Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia
    Ulrike Bacher
    Department for Stem Cell Transplantation, University of Hamburg Eppendorf, Germany
    ScientificWorldJournal 11:310-9. 2011
    ..This emphasizes the need for an expansion of the panel of MRD markers in the transplant setting...
  4. doi request reprint Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Martinistr 52, 20246 Hamburg, Germany
    Cancer Genet Cytogenet 203:169-75. 2010
    ..25). This study underlines the genetic heterogeneity of MGUS similar to PCM. Genetic analysis might contribute to more diversified monitoring strategies for MGUS patients...
  5. doi request reprint Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1649-57. 2010
    ..001). Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis...
  6. doi request reprint Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1-11. 2010
    ..Consequently, in the near future, risk stratification in MDS might incorporate additional diagnostic tools and categorization systems aimed at improving the timing and indication for SCT in this complex disorder...
  7. doi request reprint Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Germany
    Clin Exp Med 10:205-8. 2010
    ..Further, the MSCs remain of recipient origin after allogeneic SCT, which might contribute to the increased risk of graft dysfunction or failure in myelofibrosis patients after allogeneic transplantation...
  8. doi request reprint Safety of conditioning agents for allogeneic haematopoietic transplantation
    Ulrike Bacher
    University Cancer Center Hamburg, Department of Stem Cell Transplantation, Martinistr 52, 20246 Hamburg, Germany
    Expert Opin Drug Saf 8:305-15. 2009
    ....
  9. doi request reprint Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University Medical Center Hamburg UCCH, Martinistr 52, Hamburg 20246, Germany
    Ann Hematol 88:1207-13. 2009
    ..Some markers are strongly associated with one of these disorders and can be helpful for differential diagnosis especially in difficult cases...
  10. doi request reprint Interactive diagnostics in the indication to allogeneic SCT in AML
    U Bacher
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Bone Marrow Transplant 43:745-56. 2009
    ..Thus, the optimization of the indication to allo-SCT is an ongoing process that should remain in continuous interaction with the increasing panel of known genetic markers and diagnostic methods...
  11. doi request reprint The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004
    Ulrike Bacher
    Interdisziplinäre Klinik für Stammzelltransplantation, Universitäres Cancer Center Hamburg UCCH, Martinistr 52, 20246 Hamburg, Germany
    Ann Hematol 88:1237-47. 2009
    ..This study demonstrates that allo-SCT still has an important role in advanced CML, which emphasizes the need for optimized transplantation strategies for these high-risk patients...
  12. doi request reprint Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University of Hamburg, Germany
    Exp Hematol 37:135-42. 2009
    ..Nucleophosmin (NPM1) mutations, with their high frequency in AML, were suggested to represent suitable MRD markers, but so far no study has evaluated their usefulness in the posttransplantation period...
  13. doi request reprint Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
    U Bacher
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 42:145-57. 2008
    ..Standardization of the different diagnostic techniques and of the intervals in the post transplantation period is urgently needed also in other myeloid malignancies and should be focus of future studies...
  14. doi request reprint Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients
    N Kroger
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 48:403-7. 2013
    ..Toxicity-reduced myeloablative allograft followed by lenalidomide maintenance is feasible and effective in relapsed patients with MM, but the induction of GvHD should be considered...
  15. ncbi request reprint Donor choice according to age for allo-SCT for AML in complete remission
    F Ayuk
    Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 48:1028-32. 2013
    ..022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD...
  16. doi request reprint Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT
    H Alchalby
    Clinic for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 45:1404-7. 2010
    ..We conclude that MPLW515L can be cleared after allo-SCT and hence may be used as an MRD marker in a proportion of JAK2V617F-negative MF patients...
  17. doi request reprint Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
    G Schilling
    Department of Oncology and Hematology, Medical Clinic II, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 22:1250-5. 2008
    ..Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies...
  18. doi request reprint Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells
    M Lioznov
    Department for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 45:349-53. 2010
    ....
  19. doi request reprint EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT
    S Ocheni
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 42:181-6. 2008
    ....
  20. doi request reprint Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    E Klyuchnikov
    Department of Stem Cell Transplantation, University Cancer Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 49:1-7. 2014
    ..It is hoped that this review will promote the development of prospective multicenter efforts to determine whether such patients do, in fact, benefit from earlier and/or more effective implementation of allo-HCT. ..
  21. doi request reprint Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques
    M Lioznov
    Bone Marrow Transplant 41:913-6. 2008
  22. pmc Gene expression profiling for the diagnosis of acute leukaemia
    T Haferlach
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, Munich 81377, Germany
    Br J Cancer 96:535-40. 2007
    ..This method may therefore guide therapeutic decisions and should be investigated in a diagnostic setting in parallel to established standard methods...
  23. ncbi request reprint Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH)
    U Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377, Munich, Germany
    Ann Hematol 83:349-55. 2004
    ....